This content is machine translated Results of the FOREST HCM study Symptomatic obstructive hypertrophic cardiomyopathy Myosin inhibition is considered a key therapeutic approach in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). In addition to mavacamten, aficamten is now being clinically investigated as a potentially short-acting,...…
View Post 10 min This content is machine translated Hypertrophic cardiomyopathy (HCM) Genetics and risk stratification for sudden cardiac death. Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart muscle disease. The clinical picture ranges from asymptomatic patients to manifest heart failure and sudden cardiac death (SCD). The mainstay of…
View Post 5 min This content is machine translated Guidelines at the ESC Congress 2014 What is different, what is new? Several new guidelines were also presented at this year’s ESC Congress in Barcelona. Enclosed is an overview of recommendations from pulmonary embolism, myocardial revascularization, hypertrophic cardiomyopathy, aortic disease, and noncardiac…
